Difference between revisions of "Sorafenib (Nexavar)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex")
Line 4: Line 4:
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
  
 
==Diseases for which it is established ''(work in progress)''==
 
==Diseases for which it is established ''(work in progress)''==

Revision as of 01:49, 29 June 2024

General information

Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: RAF1, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2006-07-19: Initial marketing authorization as Nexavar. Nexavar is indicated for the treatment of hepatocellular carcinoma.
  • 2006-07-19: Initial marketing authorization as Nexavar. Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
  • 2014-05-23: Extension of the indication for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.

History of changes in Health Canada indication

  • 2006-07-28: Initial notice of compliance with conditions
  • 2009-06-12: Conditions were met

History of changes in PMDA indication

Also known as

  • Code names: BAY-43-9006, BAY-54-9085
  • Brand names: Nexavar, Sorafenat, Soranib

References

  1. ↑ 1.0 1.1 1.2 Sorafenib (Nexavar) package insert
  2. ↑ Sorafenib (Nexavar) package insert (locally hosted backup)
  3. ↑ Nexavar manufacturer's website
  4. ↑ Sorafenib (Nexavar) patient drug information (Chemocare)
  5. ↑ Sorafenib (Nexavar) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Sorafenib_(Nexavar)&oldid=87513"